Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series

OBJECTIVE: The UGT1A1*28 polymorphism reduces UGT1A1 enzymatic activity, which may increase the risk of severe toxicity in patients who receive standard-dose irinotecan, such as severe neutropenia and diarrhea. This real-world study assessed the optimal irinotecan dose in terms of efficacy and toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Hsiang-Lin, Chen, Po-Jung, Chen, Yen-Cheng, Li, Ching-Chun, Chang, Tsung-Kun, Su, Wei-Chih, Yin, Tzu-Chieh, Huang, Ching-Wen, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284221/
https://www.ncbi.nlm.nih.gov/pubmed/35822291
http://dx.doi.org/10.1177/03000605221110697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284221/
https://www.ncbi.nlm.nih.gov/pubmed/35822291
http://dx.doi.org/10.1177/03000605221110697

Ejemplares similares